Cómo actuar basado en las mejores evidencias disponibles | 13 JUN 16

Epilepsia en el embarazo

Resumen de la evidencia actual respecto de las mujeres con epilepsia que están embarazadas o en plan de embarazarse.
Autor/a: Michael Owen Kinney, James Morrow Fuente: BMJ 2016;353:i2880 doi: 10.1136/bmj.i2880 (Published 2 June 2016) Epilepsy in pregnancy
INDICE:  1. Página 1 | 2. Referencias
Referencias

1 Olafsson E, Hallgrimsson JT, Hauser WA, Ludvigsson P, Gudmundsson G. Pregnancies
of women with epilepsy: a population-based study in Iceland. Epilepsia 1998;39:887-92.
doi:10.1111/j.1528-1157.1998.tb01186.x pmid:9701382.
2 Katz O, Levy A, Wiznitzer A, Sheiner E. Pregnancy and perinatal outcome in epileptic
women: a population-based study. J Matern Fetal Neonatal Med 2006;19:21-5. doi:10.
1080/14767050500434096 pmid:16492586.
3 Kotsopoulos IA, van Merode T, Kessels FG, de Krom MC, Knottnerus JA. Systematic
review and meta-analysis of incidence studies of epilepsy and unprovoked seizures.
Epilepsia 2002;43:1402-9. doi:10.1046/j.1528-1157.2002.t01-1-26901.x pmid:12423392.
4 Bjørk MH, Veiby G, Reiter SC, et al. Depression and anxiety in women with epilepsy
during pregnancy and after delivery: a prospective population-based cohort study on
frequency, risk factors, medication, and prognosis. Epilepsia 2015;56:28-39. doi:10.1111/
epi.12884 pmid:25524160.
5 Turner K, Piazzini A, Franza A, Canger R, Canevini MP, Marconi AM. Do women with
epilepsy have more fear of childbirth during pregnancy compared with women without
epilepsy? A case-control study. Birth 2008;35:147-52. doi:10.1111/j.1523-536X.2008.
00228.x pmid:18507586.
6 Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy:
a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg
Psychiatry 2006;77:193-8. doi:10.1136/jnnp.2005.074203 pmid:16157661.
7 Harden CL, Hopp J, Ting TY, et al. American Academy of Neurology American Epilepsy
Society. Management issues for women with epilepsy-Focus on pregnancy (an
evidence-based review): I. Obstetrical complications and change in seizure frequency:
Report of the Quality Standards Subcommittee and Therapeutics and Technology
Assessment Subcommittee of the American Academy of Neurology and the American
Epilepsy Society. Epilepsia 2009;50:1229-36. doi:10.1111/j.1528-1167.2009.02128.x pmid:
19496807.
8 Vajda FJ, Graham J, Roten A, Lander CM, O’Brien TJ, Eadie M. Teratogenicity of the
newer antiepileptic drugs--the Australian experience. J Clin Neurosci 2012;19:57-9. doi:
10.1016/j.jocn.2011.08.003 pmid:22104350.
9 Hernández-Díaz S, Smith CR, Shen A, et al. North American AED Pregnancy
Registry North American AED Pregnancy Registry. Comparative safety of antiepileptic
drugs during pregnancy. Neurology 2012;78:1692-9. doi:10.1212/WNL.
0b013e3182574f39 pmid:22551726.
10 Tomson T, Battino D, Bonizzoni E, et al. EURAP study group. Dose-dependent risk of
malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and
pregnancy registry. Lancet Neurol 2011;10:609-17. doi:10.1016/S1474-4422(11)70107-
7 pmid:21652013.
11 Cunnington MC, Weil JG, Messenheimer JA, Ferber S, Yerby M, Tennis P. Final results
from 18 years of the International Lamotrigine Pregnancy Registry. Neurology
2011;76:1817-23. doi:10.1212/WNL.0b013e31821ccd18 pmid:21606453.
12 Perucca E. Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurol
2005;4:781-6. doi:10.1016/S1474-4422(05)70224-6 pmid:16239185.
13 Hunt S, Russell A, Smithson WH, et al. UK Epilepsy and Pregnancy Register. Topiramate
in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register.
Neurology 2008;71:272-6. doi:10.1212/01.wnl.0000318293.28278.33 pmid:18645165.
14 Mawhinney E, Craig J, Morrow J, et al. Levetiracetam in pregnancy: results from the UK
and Ireland epilepsy and pregnancy registers. Neurology 2013;80:400-5. doi:10.1212/
WNL.0b013e31827f0874 pmid:23303847.
15 Holmes LB, Mittendorf R, Shen A, Smith CR, Hernandez-Diaz S. Fetal effects of
anticonvulsant polytherapies: different risks from different drug combinations. Arch Neurol
2011;68:1275-81. doi:10.1001/archneurol.2011.133 pmid:21670385.
16 Tomson T, Battino D, Bonizzoni E, et al. EURAP Study Group. Dose-dependent
teratogenicity of valproate in mono-and polytherapy. Neurology 2015;85:866-72. doi:10.
1212/WNL.0000000000001772 pmid:26085607.
17 Mawhinney E, Campbell J, Craig J, et al. Valproate and the risk for congenital
malformations: Is formulation and dosage regime important?Seizure 2012;21:215-8. doi:
10.1016/j.seizure.2012.01.005 pmid:22364656.
18 Bromley R, Weston J, Adab N, et al. Treatment for epilepsy in pregnancy:
neurodevelopmental outcomes in the child. Cochrane Database Syst Rev
2014;10:CD010236.pmid:25354543.
19 Shallcross R, Bromley RL, Irwin B, Bonnett LJ, Morrow J, Baker GA. Liverpool Manchester
Neurodevelopment Group UK Epilepsy and Pregnancy Register. Child development
following in utero exposure: levetiracetam vs sodium valproate. Neurology 2011;76:383-9.
doi:10.1212/WNL.0b013e3182088297 pmid:21263139.
20 Shallcross R, Bromley RL, Cheyne CP, et al. Liverpool and Manchester Neurodevelopment
Group UK Epilepsy and Pregnancy Register. In utero exposure to levetiracetam vs
valproate: development and language at 3 years of age. Neurology 2014;82:213-21. doi:
10.1212/WNL.0000000000000030 pmid:24401687.
21 Bromley RL, Mawer GE, Briggs M, et al. Liverpool and Manchester Neurodevelopment
Group. The prevalence of neurodevelopmental disorders in children prenatally exposed
to antiepileptic drugs. J Neurol Neurosurg Psychiatry 2013;84:637-43. doi:10.1136/jnnp-
2012-304270 pmid:23370617.
22 Bromley RL, Mawer G, Clayton-Smith J, Baker GA. Liverpool and Manchester
Neurodevelopment Group. Autism spectrum disorders following in utero exposure to
antiepileptic drugs. Neurology 2008;71:1923-4. doi:10.1212/01.wnl.0000339399.64213.
1a pmid:19047565.
23 Campbell E, Kennedy F, Russell A, et al. Malformation risks of antiepileptic drug
monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and
Pregnancy Registers. J Neurol Neurosurg Psychiatry 2014;85:1029-34. doi:10.1136/jnnp-
2013-306318 pmid:24444855.
24 Edey S, Moran N, Nashef L. SUDEP and epilepsy-related mortality in pregnancy. Epilepsia
2014;55:e72-4. doi:10.1111/epi.12621 pmid:24754364.
25 Aurlien D, Larsen JP, Gjerstad L, Taubøll E. Increased risk of sudden unexpected death
in epilepsy in females using lamotrigine: a nested, case-control study. Epilepsia
2012;53:258-66. doi:10.1111/j.1528-1167.2011.03334.x pmid:22126371.
26 Battino D, Tomson T, Bonizzoni E, et al. EURAP Study Group. Seizure control and
treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy
registry. Epilepsia 2013;54:1621-7. doi:10.1111/epi.12302 pmid:23848605.
27 Pennell PB. Antiepileptic drugs during pregnancy: what is known and which AEDs seem
to be safest?Epilepsia 2008;49(Suppl 9):43-55. doi:10.1111/j.1528-1167.2008.01926.
x pmid:19087117.
28 EURAP Study Group. Seizure control and treatment in pregnancy: observations from
the EURAP epilepsy pregnancy registry. Neurology 2006;66:354-60. doi:10.1212/01.wnl.
0000195888.51845.80 pmid:16382034.
29 Weckesser A, Denny E. Women living with epilepsy, experiences of pregnancy and
reproductive health: a review of the literature. Seizure 2013;22:91-8. doi:10.1016/j.seizure.
2012.11.001 pmid:23182977.
30 McGrath A, Sharpe L, Lah S, Parratt K. Pregnancy-related knowledge and information
needs of women with epilepsy: a systematic review. Epilepsy Behav 2014;31:246-55. doi:
10.1016/j.yebeh.2013.09.044 pmid:24210460.
31 Crawford P, Hudson S. Understanding the information needs of women with epilepsy at
different lifestages: results of the ‘Ideal World’ survey. Seizure 2003;12:502-7. doi:10.
1016/S1059-1311(03)00085-2 pmid:12967580.
32 Campbell E, Hunt S, Kinney MO, et al. The effect of socioeconomic status on treatment
and pregnancy outcomes in women with epilepsy in Scotland. Epilepsy Behav
2013;28:354-7. doi:10.1016/j.yebeh.2013.05.019 pmid:23827318.
33 Pashley S, O’Donoghue MF. The safety of anti-epileptic drug regimens: a qualitative study
of factors determining the success of counselling women before conception. J Fam Plann
Reprod Health Care 2009;35:153-6. doi:10.1783/147118909788708002 pmid:19622204.
34 Maternal, Newborn and Infant Clinical Outcome Review Programme. MBRRACE. Saving
Lives, Improving Mothers’ Care Lessons learned to inform future maternity care from the
UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2009-2012.
[Published Online December 2012] https://www.npeu.ox.ac.uk/downloads/files/mbrrace-
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2016;353:i2880 doi: 10.1136/bmj.i2880 (Published 2 June 2016) Page 5 of 8
PRACTICE
uk/reports/Saving%20Lives%20Improving%20Mothers%20Care%20report%202014%
20Full.pdf [Accessed 23 November 15].
35 Sahoo S, Klein P. Maternal complex partial seizure associated with fetal distress. Arch
Neurol 2005;62:1304-5. doi:10.1001/archneur.62.8.1304 pmid:16087773.
36 Tinker SC, Reefhuis J, Dellinger AM, Jamieson DJ. National Birth Defects Prevention
Study. Epidemiology of maternal injuries during pregnancy in a population-based study,
1997-2005. J Womens Health (Larchmt) 2010;19:2211-8. doi:10.1089/jwh.2010.2160 pmid:
21034174.
37 Devinsky O, Feldmann E, Hainline B. Advances in neurology. Vol 64: Neurological
complications of pregnancy. Raven Press, 1994.
38 Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with
epilepsy. J Neurol Neurosurg Psychiatry 2004;75:1575-83. doi:10.1136/jnnp.2003.
029132 pmid:15491979.
39 Dlouhy BJ, Gehlbach BK, Richerson GB. Sudden unexpected death in epilepsy: basic
mechanisms and clinical implications for prevention. J Neurol Neurosurg Psychiatry
2016;87:402-13.pmid:26979537.
40 Winterbottom JB, Smyth RM, Jacoby A, Baker GA. Preconception counselling for women
with epilepsy to reduce adverse pregnancy outcome. Cochrane Database Syst Rev
2008;(3):CD006645.pmid:18646164.
41 Winterbottom J, Smyth R, Jacoby A, Baker G. The effectiveness of preconception
counseling to reduce adverse pregnancy outcome in women with epilepsy: what’s the
evidence?Epilepsy Behav 2009;14:273-9. doi:10.1016/j.yebeh.2008.11.008 pmid:
19100341.
42 Floyd RL, Jack BW, Cefalo R, et al. The clinical content of preconception care: alcohol,
tobacco, and illicit drug exposures. Am J Obstet Gynecol 2008;199(Suppl 2):S333-9. doi:
10.1016/j.ajog.2008.09.018 pmid:19081427.
43 Lassi ZS, Imam AM, Dean SV, Bhutta ZA. Preconception care: caffeine, smoking, alcohol,
drugs and other environmental chemical/radiation exposure. Reprod Health 2014;11(Suppl
3):S6. doi:10.1186/1742-4755-11-S3-S6. pmid:25415846.
44 National Institute for Health and Clinical Excellence. Epilepsies: diagnosis and management
(Clinical guidaeline 137). 2012. www.nice.org.uk/guidance/cg137.
45 Scottish Intercollegiate Guidelines Network. Diagnosis and management of epilepsy in
adults. SIGN, 2015.
46 Tomson T, Marson A, Boon P, et al. Valproate in the treatment of epilepsy in girls and
women of childbearing potential. Epilepsia 2015;56:1006-19. doi:10.1111/epi.13021 pmid:
25851171.
47 Crawford P, Appleton R, Betts T, Duncan J, Guthrie E, Morrow J. The Women with Epilepsy
Guidelines Development Group. Best practice guidelines for the management of women
with epilepsy. Seizure 1999;8:201-17. doi:10.1053/seiz.1999.0295 pmid:10452918.
48 Harden CL, Pennell PB, Koppel BS, et al. American Academy of Neurology American
Epilepsy Society. Management issues for women with epilepsy--focus on pregnancy (an
evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: Report
of the Quality Standards Subcommittee and Therapeutics and Technology Assessment
Subcommittee of the American Academy of Neurology and the American Epilepsy Society.
Epilepsia 2009;50:1247-55. doi:10.1111/j.1528-1167.2009.02130.x pmid:19507305.
49 Morrow JI, Hunt SJ, Russell AJ, et al. Folic acid use and major congenital malformations
in offspring of women with epilepsy: a prospective study from the UK Epilepsy and
Pregnancy Register. J Neurol Neurosurg Psychiatry 2009;80:506-11. doi:10.1136/jnnp.
2008.156109 pmid:18977812.
50 Meador KJ, Baker GA, Browning N, et al. NEAD Study Group. Fetal antiepileptic drug
exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational
study. Lancet Neurol 2013;12:244-52. doi:10.1016/S1474-4422(12)70323-X pmid:
23352199.
51 Pittschieler S, Brezinka C, Jahn B, et al. Spontaneous abortion and the prophylactic effect
of folic acid supplementation in epileptic women undergoing antiepileptic therapy. J Neurol
2008;255:1926-31. doi:10.1007/s00415-008-0029-1 pmid:18677647.
52 Asadi-Pooya AA. High dose folic acid supplementation in women with epilepsy: are we
sure it is safe?Seizure 2015;27:51-3. doi:10.1016/j.seizure.2015.02.030 pmid:25891927.
53 Wellings K, Jones KG, Mercer CH, et al. The prevalence of unplanned pregnancy and
associated factors in Britain: findings from the third National Survey of Sexual Attitudes
and Lifestyles (Natsal-3). Lancet 2013;382:1807-16. doi:10.1016/S0140-6736(13)62071-
1 pmid:24286786.
54 Betts T, Fox C. Proactive pre-conception counselling for women with epilepsy-is it
effective?Seizure 1999;8:322-7. doi:10.1053/seiz.1999.0325 pmid:10512771.
55 Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N
Engl J Med 2001;344:1132-8. doi:10.1056/NEJM200104123441504 pmid:11297704.
56 Update on Overall Prevalence of Major Birth Defects—Atlanta. Georgia, 1978-2005. JAMA
2008;299:756-8doi:10.1001/jama.299.7.756.
57 Fried S, Kozer E, Nulman I, Einarson TR, Koren G. Malformation rates in children of
women with untreated epilepsy: a meta-analysis. Drug Saf 2004;27:197-202. doi:10.2165/
00002018-200427030-00004 pmid:14756581.
58 Tomson T, Battino D, Craig J, et al. ILAE Commission on Therapeutic Strategies.
Pregnancy registries: differences, similarities, and possible harmonization. Epilepsia
2010;51:909-15. doi:10.1111/j.1528-1167.2010.02525.x pmid:20196792.
59 Meador KJ, Pennell PB, Harden CL, et al. HOPE Work Group. Pregnancy registries in
epilepsy: a consensus statement on health outcomes. Neurology 2008;71:1109-17. doi:
10.1212/01.wnl.0000316199.92256.af pmid:18703463.
60 Tomson T, Battino D, Perucca E. Valproic acid after five decades of use in epilepsy: time
to reconsider the indications of a time-honoured drug. Lancet Neurol 2015;15:210-8. doi:
10.1016/S1474-4422(15)00314-2 pmid:26655849.
61 Jentink J, Loane MA, Dolk H, et al. EUROCAT Antiepileptic Study Working Group. Valproic
acid monotherapy in pregnancy and major congenital malformations. N Engl J Med
2010;362:2185-93. doi:10.1056/NEJMoa0907328 pmid:20558369.
62 Vajda FJ, O’Brien TJ, Graham JE, Lander CM, Eadie MJ. Dose dependence of fetal
malformations associated with valproate. Neurology 2013;81:999-1003. doi:10.1212/WNL.
0b013e3182a43e81 pmid:23911758.
63 Christensen J, Grønborg TK, Sørensen MJ, et al. Prenatal valproate exposure and risk
of autism spectrum disorders and childhood autism. JAMA 2013;309:1696-703. doi:10.
1001/jama.2013.2270 pmid:23613074.
64 Cummings C, Stewart M, Stevenson M, Morrow J, Nelson J. Neurodevelopment of children
exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child
2011;96:643-7. doi:10.1136/adc.2009.176990 pmid:21415043.
65 Moore SJ, Turnpenny P, Quinn A, et al. A clinical study of 57 children with fetal
anticonvulsant syndromes. J Med Genet 2000;37:489-97. doi:10.1136/jmg.37.7.489 pmid:
10882750.
66 Dean JC, Hailey H, Moore SJ, Lloyd DJ, Turnpenny PD, Little J. Long term health and
neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Genet
2002;39:251-9. doi:10.1136/jmg.39.4.251 pmid:11950853.
67 Campbell E, Devenney E, Morrow J, et al. Recurrence risk of congenital malformations
in infants exposed to antiepileptic drugs in utero. Epilepsia 2013;54:165-71. doi:10.1111/
epi.12001 pmid:23167802.
68 Vajda FJ, O’Brien TJ, Lander CM, Graham J, Roten A, Eadie MJ. Teratogenesis in
repeated pregnancies in antiepileptic drug-treated women. Epilepsia 2013;54:181-6. doi:
10.1111/j.1528-1167.2012.03625.x pmid:22882134.
69 Marson AG, Al-Kharusi AM, Alwaidh M, et al. SANAD Study group. The SANAD study of
effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable
epilepsy: an unblinded randomised controlled trial. Lancet 2007;369:1016-26. doi:10.
1016/S0140-6736(07)60461-9 pmid:17382828.
70 Harden CL, Meador KJ, Pennell PB, et al. American Academy of Neurology American
Epilepsy Society. Management issues for women with epilepsy-Focus on pregnancy (an
evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality
Standards Subcommittee and Therapeutics and Technology Subcommittee of the American
Academy of Neurology and the American Epilepsy Society. Epilepsia 2009;50:1237-46.
doi:10.1111/j.1528-1167.2009.02129.x pmid:19507301.
71 National Institute for Health Research. Empire: antiepileptic drug monitoring in pregnancy.
2013. www.nets.nihr.ac.uk/__data/assets/pdf_file/0019/54550/PRO-09-55-38.pdf.
72 Reisinger TL, Newman M, Loring DW, Pennell PB, Meador KJ. Antiepileptic drug clearance
and seizure frequency during pregnancy in women with epilepsy. Epilepsy Behav
2013;29:13-8. doi:10.1016/j.yebeh.2013.06.026 pmid:23911354.
73 Pennell PB, Peng L, Newport DJ, et al. Lamotrigine in pregnancy: clearance, therapeutic
drug monitoring, and seizure frequency. Neurology 2008;70:2130-6. doi:10.1212/01.wnl.
0000289511.20864.2a pmid:18046009.
74 Tomson T, Palm R, Källén K, et al. Pharmacokinetics of levetiracetam during pregnancy,
delivery, in the neonatal period, and lactation. Epilepsia 2007;48:1111-6. doi:10.1111/j.
1528-1167.2007.01032.x pmid:17381438.
75 Westin AA, Reimers A, Helde G, Nakken KO, Brodtkorb E. Serum concentration/dose
ratio of levetiracetam before, during and after pregnancy. Seizure 2008;17:192-8. doi:10.
1016/j.seizure.2007.11.027 pmid:18180176.
76 Sabers A, Petrenaite V. Seizure frequency in pregnant women treated with lamotrigine
monotherapy. Epilepsia 2009;50:2163-6. doi:10.1111/j.1528-1167.2009.02166.x pmid:
19490048.
77 Sabers A. Algorithm for lamotrigine dose adjustment before, during, and after pregnancy.
Acta Neurol Scand 2012;126:e1-4. doi:10.1111/j.1600-0404.2011.01627.x pmid:22150770.
78 Tomson T, Hiilesmaa V. Epilepsy in pregnancy. BMJ 2007;335:769-73. doi:10.1136/bmj.
39266.473113.BE pmid:17932208.
74 Tomson T, Palm R, Källén K, et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia 2007;48:1111-6. doi:10.1111/j.1528-1167.2007.01032.x pmid:17381438. 75 Westin AA, Reimers A, Helde G, Nakken KO, Brodtkorb E. Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. Seizure 2008;17:192-8. doi:10.1016/j.seizure.2007.11.027 pmid:18180176.
76 Sabers A, Petrenaite V. Seizure frequency in pregnant women treated with lamotrigine monotherapy. Epilepsia 2009;50:2163-6. doi:10.1111/j.1528-1167.2009.02166.x pmid:19490048.
77 Sabers A. Algorithm for lamotrigine dose adjustment before, during, and after pregnancy. Acta Neurol Scand 2012;126:e1-4. doi:10.1111/j.1600-0404.2011.01627.x pmid:22150770.
78 Tomson T, Hiilesmaa V. Epilepsy in pregnancy. BMJ 2007;335:769-73. doi:10.1136/bmj.39266.473113.BE pmid:17932208.

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2022